Literature DB >> 8832528

Infections in neutropenic patients I: aetiology.

P Engervall1, M Björkholm.   

Abstract

Improvement in supportive care including the introduction of new antibiotics, antiviral and antifungal agents and haematopoietic growth factors have all contributed to a decreased chemotherapy-related mortality and morbidity in cancer patients. However, infections/septic shock during neutropenia still constitutes a major threat to these patients. Most patients develop fever during neutropenia and in 20-40% a manifest bacteremia is documented. In patients with prolonged neutropenia, the risk for fungal infections is increased. The spectrum of bacterial, fungal and viral infections in the neutropenic patient is reviewed.

Entities:  

Mesh:

Year:  1995        PMID: 8832528      PMCID: PMC7101772          DOI: 10.1007/bf02990570

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  61 in total

1.  Influenza B in transplant patients.

Authors:  J Aschan; O Ringdén; P Ljungman; J Andersson; I Lewensohn-Fuchs; M Forsgren
Journal:  Scand J Infect Dis       Date:  1989

Review 2.  Herpes simplex infections in hematologic malignancies.

Authors:  S A Muller; E C Herrmann; R K Winkelmann
Journal:  Am J Med       Date:  1972-01       Impact factor: 4.965

3.  Invasive pulmonary aspergillosis in adult acute leukemia: clinical clues to its diagnosis.

Authors:  S L Gerson; G H Talbot; E Lusk; S Hurwitz; B L Strom; P A Cassileth
Journal:  J Clin Oncol       Date:  1985-08       Impact factor: 44.544

4.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

5.  Anorectal infections in patients with malignant diseases.

Authors:  J Glenn; D Cotton; R Wesley; P Pizzo
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

6.  Clinically significant coagulase-negative staphylococci: identification and resistance patterns.

Authors:  K Refsahl; B M Andersen
Journal:  J Hosp Infect       Date:  1992-09       Impact factor: 3.926

Review 7.  Bacteremia due to viridans streptococci in neutropenic patients: a review.

Authors:  P Y Bochud; T Calandra; P Francioli
Journal:  Am J Med       Date:  1994-09       Impact factor: 4.965

8.  Septicemia in patients with hematological disorders and neutropenia. A retrospective study of causative agents and their resistance profile.

Authors:  G Günther; M Björkholm; A Björklind; P Engervall; G Stiernstedt
Journal:  Scand J Infect Dis       Date:  1991

9.  Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia.

Authors:  R S Schwartz; F R Mackintosh; S L Schrier; P L Greenberg
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

10.  Acyclovir prophylaxis of herpes-simplex-virus infections.

Authors:  R Saral; W H Burns; O L Laskin; G W Santos; P S Lietman
Journal:  N Engl J Med       Date:  1981-07-09       Impact factor: 91.245

View more
  3 in total

1.  Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.

Authors:  A Jimeno; A Arcediano; S Bazares; M L Amador; L González-Cortijo; E Ciruelos; L Robles; D Castellano; L Paz-Ares; C Lumbreras; J Hornedo; H Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2006-12       Impact factor: 3.405

2.  A study of bacteremia in febrile neutropenic patients at a tertiary-care hospital with special reference to anaerobes.

Authors:  P Mathur; R Chaudhry; L Kumar; A Kapil; B Dhawan
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

3.  Totally implantable subcutaneous port system versus central venous catheter placed before induction chemotherapy in patients with acute leukaemia-a randomized study.

Authors:  Eva Johansson; Magnus Björkholm; Hjördis Björvell; Robert Hast; Rabbe Takolander; Per Olofsson; Lars Backman; Eddie Weitzberg; Per Engervall
Journal:  Support Care Cancer       Date:  2003-11-25       Impact factor: 3.603

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.